Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
复制标题
DOI：
10.1016/j.vaccine.2021.05.056
复制
发表时间：
2021-06-29
期刊：
影响因子：
5.5
通讯作者：
Acharya NR
中科院分区：
文献类型：
--
作者：
Sun Y;Jackson K;Dalmon CA;Shapiro BL;Nie S;Wong C;Arnold BF;Porco TC;Acharya NR
背景：几十年来，美国带状疱疹（HZ）的发病率一直呈上升趋势。重组带状疱疹疫苗（RZV）的临床试验表明，疫苗预防带状疱疹的效力超过90%。然而，在临床试验之外，关于其有效性的信息有限，以及它对带状疱疹（HZO）的有效性。方法使用来自夏威夷凯撒医疗机构（KPH）的去识别电子健康记录数据库进行这项回顾性队列研究，以评估重组带状疱疹疫苗在2018年1月1日至2019年12月31日期间，在符合RZV年龄条件之前连续入组KPH≥365天且无HZ病史的免疫能力、符合疫苗年龄要求的个体中抗HZ和HZO的有效性。结果共纳入78 356例成人，其中11 864例（15.1%）接种了2剂重组带状疱疹疫苗。在接种疫苗的人群中，HZ的发病率为每10万人年325.6例（95% CI: 217.7 - 464.4），而在未接种疫苗的人群中，HZ的发病率为每10万人年1063.3例（95% CI: 1006.0 - 1122.8）。接种疫苗组的HZO发病率为每10万人年11.9例（95% CI: 0.7 - 52.3），而未接种疫苗组为72.1例（95% CI: 58.0 - 88.3）。RZV对HZ的有效率为83.5% (95% CI: 74.9% ~ 89.2%)，对HZO的有效率为93.3% （95% CI: 48.7% ~ 99.1%）。结论：srzv在美国的临床试验环境之外显示出对HZ和HZO的高有效性。疫苗覆盖率低，强调需要公共卫生努力增加疫苗接种，以减少HZ和HZO的发病率。
BackgroundThe incidence of herpes zoster (HZ) has been on the rise for decades in the United States. Clinical trials for the recombinant zoster vaccine (RZV) demonstrated vaccine efficacy of over 90% in preventing herpes zoster. However, there is limited information on its effectiveness outside of a clinical trial setting, as well as its effectiveness against herpes zoster ophthalmicus (HZO).MethodsA de-identified electronic health records database from Kaiser Permanente Hawaii (KPH) was used to conduct this retrospective cohort study to assess the effectiveness of the recombinant zoster vaccine against HZ and HZO in immunocompetent, vaccine age-eligible individuals without a prior history of HZ, who were continuously enrolled in KPH for ≥365 days prior to becoming age-eligible for RZV between January 1, 2018, through December 31, 2019.ResultsA total of 78 356 adults were included in this study, with 11 864 (15.1%) adults receiving two valid doses of the recombinant zoster vaccine. The incidence rate of HZ was 325.6 (95% CI: 217.7 to 464.4) cases per 100 000 person-years in vaccinated persons compared to 1063.3 cases per 100 000 person-years (95% CI: 1006.0 to 1122.8) in the unvaccinated group. The incidence rate of HZO was 11.9 (95% CI: 0.7 to 52.3) cases per 100 000 person-years in the vaccinated group compared to 72.1 (95% CI: 58.0 to 88.3) in the unvaccinated group. RZV was 83.5% (95% CI: 74.9% to 89.2%) effective against HZ and 93.3% (95% CI: 48.7% to 99.1%) effective against HZO.ConclusionsRZV has demonstrated high effectiveness against both HZ and HZO outside of a clinical trial setting in the United States. Vaccine coverage is low, emphasizing the need for public health efforts to increase vaccination to reduce morbidity from HZ and HZO.
登录
查看更多内容
DOI：
10.1056/nejmcp1302674
发表时间：
2013-07-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
Cohen JI
通讯作者：
Cohen JI
影响因子：
2
作者：
Austin PC
通讯作者：
Austin PC
影响因子：
13.7
作者：
Kong, Christina L.;Thompson, Ryan R.;Acharya, Nisha R.
通讯作者：
Acharya, Nisha R.
影响因子：
7.2
作者：
DEYO, RA;CHERKIN, DC;CIOL, MA
通讯作者：
CIOL, MA
影响因子：
5
作者：
Baxter, Roger;Bartlett, Joan;Saddier, Patricia
通讯作者：
Saddier, Patricia